Shares of drugmaker Eli Lilly (LLY) got a price target bump by Mizuho on the strength of weight-loss drug tirzepatide. I need to lose about 15 pounds, but I am working on it without taking another drug. Let's check out the charts and indicators.
More from Investing
These recently downgraded names are displaying both quantitative and technical deterioration.
These kind of names are in short supply in the current market.
With the possibility of a sale of MANU getting kicked around, it's game-on for owners of the shares.
Let's explore MLPs that can offer above-average distribution yields.